Research & Trials

CRMD’s research program is one of the largest in the country for a community-based practice and rivals those of some of the largest academic medical centers.

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. Clinical trials used in drug development are sometimes described by phase. These phases are defined By the Food and Drug Administration – each phase is designed to answer a separate research question.

  • Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
  • Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
  • Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
  • Phase IV: Studies are done after the drug or treatment has been marketed to gather information on the drug’s effect in various populations and any side effects associated with long-term use.

Currently enrolling:

Wet Age-Related Macular Degeneration

Alcon-Osprey-A prospective, Randomized, Double-Masked, Phase 2, Multi center, Two arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA in subjects with Exudative Age- Related Macular Degeneration. (Wet macular degeneration)

ClinicalTrials.gov identifier NCT01796964

Lpath-003/Nexus Study-A Phase2a, Multi-center, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP as Monotherapy or Adjunctive Therapy to Lucentis/Avastin versus Lucentis /Avastin Alone for the treatment of Subjects with Choroidal Neovascularization Secondary to Age related Macular Degeneration.

ClinicalTrials.gov identifier NCT01414153

Dry Age Related Macular Degeneration (Geographic atrophy)

LFG316A2203-A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-Related Macular Degeneration.

ClinicalTrials.gov identifier NCT01527500

Uveitis

Xoma-A Randomized, Double –masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-Uveitis Currently Controlled with Systemic Treatment. (Uveitis)

ClinicalTrials.gov identifier NCT01747538

Santen/Sakura- A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis. (Soon to stop enrollment)

ClinicalTrials.gov identifier NCT01358266

Enrolling soon           

Wet Age-Related Macular Degeneration

Re-View- An Open-Label Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Afibercept Injection) in patients with Neovascular Age-Related Macular Degeneration (Wet) With emphasis on Endothelial Cell Counts using a specular microscope.

ClinicalTrials.gov identifier NCT01722045

Upcoming studies

Comrade-B-A 6 month Multicenter, Randomized, Double-Masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal implant in Patients with Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion. (BRVO)

ClinicalTrials.gov identifier NCT01396057

ORION-A phase 4 investigational study on the safety and effectiveness of treating Central Retinal Vein Occlusions (CRVO) associated Macular edema with a combination of 0.7mg of Ozurdex and 0.5 mg Lucentis, given as separate injections into the eye.

ClinicalTrials.gov identifier NCT0187722